Therefore, the CD16-CR has the potential to be a powerful tool against highly heterogeneous or genetically unstable cancer types resistant to conventional CAR-T cell therapy, because it reduces the probability of antigen escape. The gene discussed is FCGR3A; the disease is cancer.